Prioritize Your Most Promising LNP Candidates—While Saving Time and Money
Gain confidence in the clinical safety of your lipid nanoparticle (LNP) vector candidates by testing them in a human-relevant model ahead of costly animal studies.
The Cost of the Status Quo
How Moderna is using Organ-Chips to improve their LNP research
Samantha Atkins, PhD, is a scientist in the Investigative Pathology division at Moderna. Her goal is to de-risk their LNP candidates to make them safer before they progress into NHP studies. To increase the efficiency of her research program, Dr. Atkins has started using the Emulate human Liver-Chip to screen for LNP-mediated toxicity instead of relying solely on NHPs.
In a simple cost analysis, Dr. Atkins found that she was able to screen 35 novel LNPs in the Liver-Chip during a course of experiments that took 18 months at a total cost of $325,000. If she were to screen the same number of LNPs using traditional NHP studies, it would have cost Moderna over $5,000,000 and taken over 60 months to complete.
Simply by incorporating Liver-Chips into her workflow, she is able to down-select LNPs over 4x faster and at a fraction of the cost of NHP studies.
Learn more by watching Dr. Atkins’ full presentation here.
Calculate your potential savings
**Pricing is based on average market costs and a sample size of 3 per test condition. NHP study estimates exclude the cost of controls. Organ-Chip study cost and length are based on the purchase of 2 Zoë-CM2 Culture Modules.
Are you ready to expedite your LNP program?
By incorporating Organ-Chip studies into your LNP development workflow, you can rapidly iterate on vector design in a human-relevant model before moving forward to costly animal studies.
Learn more about how Organ-Chips can accelerate your vector optimization and give you higher confidence that your results will translate to the clinic.
